Robert Macleod
Company: ADARx
Job title: Chief Scientific Officer
Seminars:
ADX-038, a Long-Acting CFB siRNA Therapeutic for Multiple Complement Mediated Diseases 2:00 pm
Exploring the current shift towards their use as add-on therapies in hematology where C5 inhibition alone is rarely sufficient Delving into the strategic decisions for Factor B when used in addition to expensive C5 inhibitors Exploring the current shift towards their use as add-on therapies in hematology where C5 inhibition alone is rarely sufficientRead more
day: Conference Day Two
Panel Discussion: Understanding the Current Attitudes Towards Mandatory Vaccinations Before Dosing a Patient with Complement Inhibitors 4:00 pm
Re-evaluating the blanket vaccination requirements for complement inhibitors considering the emergence of novel, non-C5 complement inhibitors that show a lower infection risk compared to earlier C5 antibodies Discussing whether a blanket-approach remains justified, or whether a more nuance, risk stratified approach is warranted Navigating vaccination in acute vs chronic complement-mediated conditions, to mitigate infection risk…Read more
day: End of Day Two